// App-Quantinova.ai

: Late Breaking Abstract - Blood eosinophil counts and treatment response in COPD: analyses of IMPACT

Researchers

Presenter

  • Steven Pascoe

Principal Investigators

  • Guy Brusselle

  • Chris Compton

  • Gerard Criner

  • Mark Dransfield

  • David M.G. Halpin

  • Meilan K. Han

  • Benjamin Hartley

  • Emma Hilton

  • Peter Lange

  • Sally Lettis

  • David A. Lipson

  • David Lomas

  • Fernando J. Martinez

  • Alberto Papi

  • Nicolas Roche

  • Ralf J.P. Van Der Valk

  • Robert Wise

  • Dave Singh

Medical Centers

  • GlaxoSmithKline plc, Collegeville, United States of America

  • Glaxo-Smith Kline, Brentford, London, United Kingdom

  • Ghent University Hospital, Ghent, Belgium

  • Lewis Katz School of Medicine at Temple University, Philadelpha , United States of America

  • Division of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, United States,

  • Department of Gastroenterology, Royal Devon and Exeter Hospital, Exeter, United Kingdom

  • Statistics and Programming, Veramed Ltd, Twickenham, United Kingdom

  • University of Copenhagen, Copenhagen E, Denmark

  • GlaxoSmithKline, Uxbridge, United Kingdom

  • GSK and Perelman School of Medicine, University of Pennsylvania, Collegeville and Philadelphia, PA, United States.

  • UCL Respiratory, University College London, London, United Kingdom

  • NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, United States of America

  • Research Centre on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy,

  • Pneumologie, Cochin Hospital AP-HP, University Paris Descartes, Paris, France

  • Division of Pulmonary and Critical Care, School of Medicine, Johns Hopkins University, Baltimore, United States of America

  • University of Manchester, Manchester, United Kingdom

Locations

  • United States

  • United Kingdom

  • Belgium

  • Denmark

  • Italy

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Fluticasone furoate

  • Umeclidinium

  • Fluticasone

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Parallel Group

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved